Hikma Pharmaceuticals PLC (HKMPY)
OTHER OTC:HKMPY
Want to see HKMPY full AI Analyst Report?
Total Valuation
Hikma Pharmaceuticals has a market cap or net worth of $4.13B. The enterprise value is $5.45B.
Market Cap$4.13B
Enterprise Value$5.45B
Share Statistics
Hikma Pharmaceuticals has 106,660,385 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding106,660,385
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Hikma Pharmaceuticals’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 10.31%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)10.31%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee353.35K
Profits Per Employee42.41K
Employee Count9,500
Asset Turnover0.59
Inventory Turnover1.73
Valuation Ratios
The current PE Ratio of Hikma Pharmaceuticals is 10.6. Hikma Pharmaceuticals’s PEG ratio is 0.89.
PE Ratio10.6
PS Ratio1.38
PB Ratio1.78
Price to Fair Value1.78
Price to FCF28.48
Price to Operating Cash Flow10.98
PEG Ratio0.89
Income Statement
In the last 12 months, Hikma Pharmaceuticals had revenue of 3.36B and earned 402.94M in profits. Earnings per share was 3.66.
Revenue3.36B
Gross Profit1.44B
Operating Income569.33M
Pretax Income520.21M
Net Income402.94M
EBITDA781.82M
Earnings Per Share (EPS)3.66
Cash Flow
In the last 12 months, operating cash flow was 390.56M and capital expenditures -195.68M, giving a free cash flow of 194.89M billion.
Operating Cash Flow390.56M
Free Cash Flow194.89M
Free Cash Flow per Share1.83
Dividends & Yields
Hikma Pharmaceuticals pays an annual dividend of $0.96, resulting in a dividend yield of 4.04%
Dividend Per Share$0.96
Dividend Yield4.04%
Payout Ratio49.79%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.48
52-Week Price Change-26.43%
50-Day Moving Average38.20
200-Day Moving Average40.07
Relative Strength Index (RSI)52.95
Average Volume (3m)576.00
Important Dates
Hikma Pharmaceuticals upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Hikma Pharmaceuticals as a current ratio of 1.82, with Debt / Equity ratio of 63.59%
Current Ratio1.82
Quick Ratio1.06
Debt to Market Cap0.34
Net Debt to EBITDA1.63
Interest Coverage Ratio5.36
Taxes
In the past 12 months, Hikma Pharmaceuticals has paid 112.26M in taxes.
Income Tax112.26M
Effective Tax Rate0.22
Enterprise Valuation
Hikma Pharmaceuticals EV to EBITDA ratio is 7.55, with an EV/FCF ratio of 36.34.
EV to Sales1.76
EV to EBITDA7.55
EV to Free Cash Flow36.34
EV to Operating Cash Flow16.40
Balance Sheet
Hikma Pharmaceuticals has $354.00M in cash and marketable securities with $1.65B in debt, giving a net cash position of -$1.29B billion.
Cash & Marketable Securities$354.00M
Total Debt$1.65B
Net Cash-$1.29B
Net Cash Per Share-$12.14
Tangible Book Value Per Share$13.02
Margins
Gross margin is 41.35%, with operating margin of 16.96%, and net profit margin of 12.00%.
Gross Margin41.35%
Operating Margin16.96%
Pretax Margin15.50%
Net Profit Margin12.00%
EBITDA Margin23.29%
EBIT Margin16.96%
Analyst Forecast
The average price target for Hikma Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast7.31%
EPS Growth Forecast12.55%